 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 GLOBE NEWSWIRE -- Fluidigm Corporation Nasdaq:FLDM, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its AdvantaTM Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus. The CE-IVD mark is in conformance with the European Union In Vitro Diagnostic Directive. 